




**CONTINEUM**  
therapeutics

## Corporate Presentation

May 15, 2024



## Legal Disclaimer


This presentation by Contineum Therapeutics, Inc. (“Contineum”, “We” or “Our”) contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including without limitation statements regarding our future results of operations and financial position, future revenue, timing, progress and expected results of our clinical trials and our product development efforts, business strategy, prospects, research and development costs, timing and likelihood of success, the size of the market opportunities, as well as plans and objectives of management for future operations, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that are in some cases beyond our control and may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential” “predict,” “project,” “should,” “target,” “will” or “would” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements in this presentation are only predictions and represent our views as of the date of this presentation. Although we believe the expectations reflected in such forward-looking statements are reasonable, we cannot guarantee that the future results, advancements, discoveries, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. The forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to: we are heavily dependent on the success of PIPE-791, our lead product candidate, and PIPE-307, both of which are in the early stages of clinical development, and neither of these drug candidates may progress through clinical development or receive regulatory approval, or, even if approved, may not be successfully commercialized; the results of earlier preclinical studies and clinical trials, including those conducted by third parties, may not be predictive of future results; the regulatory approval processes of the FDA and comparable foreign regulatory authorities are unpredictable, lengthy, and time-consuming and we or our partners may not obtain regulatory approval for our drug candidates; we may not be successful in our efforts to identify and develop additional drug candidates or identify additional indications for our drug candidates; we have incurred significant operating expenses since inception and we expect that our operating expenses will continue to significantly increase for the foreseeable future; we have a limited operating history, which may make it difficult to evaluate the prospects for our future viability; we will require significant additional capital to complete the development and commercialization of our drug candidates; our license agreement with an affiliate of Johnson & Johnson may not result in the successful development of PIPE-307; we may be unable to obtain, maintain and enforce intellectual property protection for our technology and drug candidates; we currently rely on third-party contract manufacturing organizations for the production of the raw materials and clinical supplies for our drug candidates; we rely on third parties to conduct our ongoing clinical trials of PIPE-791 and PIPE-307 and expect to continue to rely on third parties to conduct our future clinical trials; we face significant competition from biotechnology, pharmaceutical, and medical device companies; our drug candidates, even if approved, may fail to achieve market acceptance by physicians, patients, third-party payors, or others in the medical community necessary for commercial success; we expect to rely on third parties for sales, marketing and distribution of any drug candidates that receive regulatory approval; and we may seek to grow our business through in-licensing transactions or otherwise by acquiring drug candidates or complementary products, technologies or businesses. We discuss these and other risks and uncertainties in greater detail in the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our periodic reports, including our most recent Form 10-Q for the period ended March 31, 2024, filed with the SEC on May 16, 2024 and other filings that we make with the SEC from time to time. Accordingly, readers should not rely upon forward-looking statements as predictions of future events. Except as required by applicable law, we undertake no obligation to update publicly or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. We operate in a very competitive and rapidly changing environment. New risks emerge from time to time, and it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances described in this presentation may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements contained in this presentation.

### *Market & Industry Data*


This presentation contains estimates, projections and other information concerning our industry, our business and the markets for our product candidates, including data regarding the estimated size of such markets and the incidence of certain medical conditions. We obtained the industry, market and similar data set from our internal estimates and research, including surveys and studies we have sponsored and/or conducted, and from published studies from third parties, including governmental agencies. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions, and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.

# Pioneering the NI&I Field with Precision

- Sizeable markets in IPF, depression and MS with high unmet medical need
- Multiple shots on goal for both clinical-stage assets
- Valuable J&J partnership on PIPE-307 focused on RRMS and depression
- Robust patent estate protects pipeline through 2040 and beyond
- Recently completed IPO; strong proforma cash balance of \$225.9M as of Q1 2024



# Balanced Development Pipeline and Targeted Discovery Platform



\* Single Phase 1b PET clinical trial of PIPE-791 for the potential treatment of IPF and Progressive MS.



## LPA1R Antagonism and PIPE-791 in Idiopathic Pulmonary Fibrosis

# LPA1R: An Important Target for Pulmonary Fibrosis

## Rationale & Unmet Need

- IPF is a **rare, irreversible, progressive interstitial lung disease** with unknown etiology
- Prognosis for **overall survival is worse than many forms of cancer**
- **Current therapies have limitations** related to side effects, tolerability, moderate efficacy and multi-daily dose regimens
- Levels of LPA are elevated in the lungs of IPF patients
- **Clinical validation** confirmed in IPF with LPA1R antagonist BMS-986278

**~130K**

Patients with IPF in the US

**~3M**

Patients with IPF Worldwide

**~60-80%**

Patients Dying From Respiratory Failure<sup>1</sup>

**2**

FDA-Approved Therapies for IPF

**0**

Approved Drugs Halt Progression of IPF


**~\$4B**

Esbriet and Ofev Combined Sales in 2022<sup>2</sup>

<sup>1</sup> Within five years of diagnosis. Clin Respir J. 2022;16:84-96

<sup>2</sup> Boehringer Ingelheim press release March 29, 2023; Roche Holdings, Inc. Annual Report 2022


# The Role of LPA1R in the Initiation and Progression of Pulmonary Fibrosis



LPA1R activation promotes recruitment of fibroblasts and collagen secretion leading to fibrosis and restrictive lung disease

LPA production and LPA1R expression increases following injury

LPA is elevated in the broncho-alveolar washings of IPF patients



LPA-induced endothelial barrier breakdown promotes further inflammation

**Blocking the LPA1R inhibits several steps in the fibrosis pathway**


# LPA1R Is a Clinically Validated Target in IPF

- Two LPA1R antagonists (BMS-986020 and BMS-986278) were shown to slow the rate of FVC decline in 26-week, placebo controlled, studies in patients with IPF
- Patients on BMS-986020 developed hepatobiliary toxicity that was later shown to be related to an off-target activity
- BMS-986278 was developed to minimize this off-target toxicity
- BMS-986278 60 mg BID required for efficacy  
→ **opportunity for an improved compound, given once daily**


## BMS Phase 2 Pulmonary Fibrosis PoC Studies\*

Compound	Indication	# of Patients	Study Length (weeks)
BMS-986020	IPF	143	26
BMS-986278	IPF	276	26
BMS-986278	PPF	123	26

\*Based on publicly available data (clinicaltrials.gov)



Adapted from Palmer et al., Chest, 2018




Adapted from Corte et al., ATS, 2023



# PIPE-791 Versus Other LPA1R Antagonists in Development



	PIPE-791	BMS-986278	BMS-986020	AMG-670
hLPA (Ca <sup>2+</sup> flux) IC <sub>50</sub>	9.9 nM	80 nM	2.0 nM	9.2 nM
Plasma protein binding, % Free (rodent)	5.7	15	0.2	0.07
Oral bioavailability %F	78%	138%	64%	4.7%
Stage of development	Phase 1	Phase 3	Phase 2 (terminated)	Phase 2



**PIPE-791 has demonstrated high oral bioavailability and low plasma protein binding, which we believe will lead to increased PIPE-791 receptor exposure with low dosing**


# PIPE-791 – *In vitro* and *In vivo* pharmacology

## Target Coverage for Antifibrotic Effect

### Summary of *In Vitro* Pharmacology



Properties	<i>In Vitro</i> Profile
Radioligand binding $K_i$ (nM)	0.752
$K_{off}$ ( $\text{min}^{-1}$ )	0.00133
LPA1 $\text{Ca}^{2+}$ mobilization (nM, 24h)	9.9

### *In Vivo* Lung LPA1R Occupancy



- PIPE-791 is a selective LPA1R antagonist with *in vitro* long receptor off rate
- PIPE-791 demonstrated dose-dependent lung LPA1R occupancy with once daily oral dosing
- Therapeutic concentration range -  $EC_{50}$  of 9 ng/mL  $\rightarrow$   $EC_{90} = 24$  ng/mL
- Clinically translatable model to establish target-occupancy relationship to de-risk dose selection

# PIPE-791 – Bleomycin-induced *In Vivo* Lung Fibrosis Model




- PIPE-791 treatment reduced injury-induced lung collagen, increased survival, and normalized body weights
- Maximal effect observed using 0.3 mg/kg with once daily dosing, representing high LPA1 lung occupancy

# Phase 1 Healthy Volunteer Study Schema and Adverse Events


## Single ascending dose cohorts

(N=8/cohort; 6 active, 2 placebo)



## Multiple ascending dose cohorts

(N=8/cohort; 6 active, 2 placebo)



- SAD4 PK >> predicted pharmacologically active range
- MAD3 extended to 14d to confirm steady-state


## Treatment emergent AEs reported in ≥ 2 subjects

AE (# of subjects)	Placebo	SAD1	SAD2	SAD3	SAD4	MAD1	MAD2	MAD3
Abdominal pain		1	1					
Nasal congestion				1				1
URI			1					2
Rhinitis				1				1
Headache	1		1		3	1		
Back pain				1	2			

- No dose-limiting AEs or toxicity
- No notable changes/pattern in clinical laboratory, ECG/telemetry, or vital signs
- Database locked: Feb 2024


# PIPE-791 Phase 1 SAD and MAD Cohort PK Profiles

**SAD:** Mean plasma concentration (ng/ml) through Day 14 [semi-log]



- SAD PK linear and dose-proportional
- $T_{1/2}$  SAD 1-4 cohorts: 55, 45, 42, 31 hours
- FED state: No overall change in AUC<sub>24</sub>; slightly delayed  $T_{max}$  and reduced  $C_{max}$

**MAD:** Mean 24-hour plasma concentration (ng/ml) through Day 7 (MAD1 and MAD2) and Day 14 MAD3 [semi-log]



- EC<sub>50</sub> and EC<sub>90</sub> receptor occupancy (based on preclinical studies) reached at 24-hour trough after single 1 mg dose

# PIPE-791: Clinical Development and PoC Plans in Pulmonary Fibrosis

2023-2024

2024

2025

**Phase 1 SAD/MAD/FED  
Healthy Volunteer Trial**

Randomized, double-blind,  
placebo-controlled  
(n = 56)

**STUDY OBJECTIVES:**

**Primary:**  
Safety and tolerability

**Secondary:**  
Pharmacokinetics


**Phase 1b  
Lung PET Study (n = 6-8)**  
*(pending MHRA authorization)*

**STUDY OBJECTIVES:**

**Primary:**  
PK/RO relationship

**Phase 2 DB-RCT Dose-Ranging**  
Idiopathic pulmonary fibrosis  
Primary: Change in FVC from Baseline to 6m  
*(pending FDA IND authorization)*

**Spirometry: Forced vital capacity**



\*GLP tox NOAEL 1000 mg/kg/day; chronic GLP tox ongoing

\*Visual representation of FVC test



## LPA1R Antagonism and PIPE-791 in Progressive MS

# Progressive MS Is an Area of Significant Unmet Need

## Rationale & Unmet Need

- MS is a chronic, immune-mediated disease of the CNS characterized by **neuroinflammation and demyelination** leading to continued **worsening of clinical disability**
- Within the CNS, the LPA1R is enriched in glial cells including microglia and oligodendrocytes
- LPA is elevated in the CSF of patients with MS
- PIPE-791 potentially promotes remyelination and reduces neuroinflammation
- Very limited treatment options for patients with Progressive MS

**~2.8M**

**Patients with MS  
Globally**

**>750K**

**Patients with  
Progressive MS Globally**

**~15%**


**Newly Diagnosed  
Patients Have PPMS<sup>1</sup>**

**~50-70%**

**Patients with RRMS  
Progress to SPMS<sup>2</sup>**





# LPA1R: Key Regulator of Remyelination and Neuroinflammation



## Blocking LPA1R Reduces Neuroinflammation and Promotes Remyelination - Demonstration in Ex Vivo Slice Cultures



### REDUCED NEUROINFLAMMATION

PIPE-791 inhibits microglia activation





### REMYELINATION

PIPE-791 promotes remyelination in an ex vivo brain slice



# PIPE-791 *In Vivo* LPA1R Receptor Occupancy




- PIPE-791 showed dose-dependent CNS LPA1R receptor occupancy with once daily oral dosing
- Correcting for plasma protein binding in rodents (96.6%), the resulting unbound  $EC_{50}$  is estimated to be 0.7 nM

# PIPE-791 Promotes Functional Remyelination and Reduces Neuroinflammation *In Vivo*


## Mouse EAE Model

Restored VEP-Latency




VEP-latency = **translatable clinical endpoint**: retinal to visual cortex speed

Increased Myelination



**Remyelination** in mouse EAE model

Reduced Neuroinflammation




Microglia accumulation – marker of local **neuroinflammation**


\*\*\*\* p<0.001; \*\*\* p<0.005; \* p<0.05.

## LPS Challenge Model


*Cxcl1*




*Cxcl10*




*Ccl5*




*Il1β*



*Il6*



*Tnfa*



\*p<0.05, \*\*\*p<0.005

Brain penetrant PIPE-791 reduces LPS-induced neuroinflammatory markers

# PIPE-791: Clinical Development and Early PoC Plans in Multiple Sclerosis

2023

**Phase 1 SAD/MAD/FED  
Healthy Volunteer Study**  
Randomized, double-blind,  
placebo-controlled  
(n = 56)

**STUDY OBJECTIVES:**

**Primary:**  
Safety and tolerability

**Secondary:**  
Pharmacokinetics

2024

**Phase 1b**  
Brain PET Study (n = 6-8)  
*(pending MHRA authorization)*


**STUDY OBJECTIVES:**

**Primary:**  
PK/RO relationship

2025

**Phase 2 DB-RCT Dose-Ranging**  
Progressive MS: PPMS/SPMS  
Primary: Change in neuro-inflammatory  
imaging biomarkers under consideration  
*(pending FDA authorization)*


Illustrative examples of  
paramagnetic lesions by MRI QSM and  
TSPO activity by PET PK11195



Paramagnetic  
lesion by MRI



Quantitative  
susceptibility  
mapping (QSM)



PK11195  
PET

\*GLP tox NOAEL 1000 mg/kg/day; chronic GLP tox ongoing



CTX-343 for Peripheral Fibrotic Diseases  
*IND submission expected in 2025*

# CTX-343 – *In vitro* and *In vivo* pharmacology



## Target Coverage for Antifibrotic Effect

### Summary of *In Vitro* and *In Vivo* Properties


Properties	<i>In Vitro</i> Profile
Radioligand binding $K_i$ (nM)	5.56 ( $IC_{50}$ : 19.5)
$K_{off}$ ( $min^{-1}$ )	0.00036
LPA1 $Ca^{2+}$ mobilization (nM)	48.1
Rodent $K_{p,uu}$ @ 2h	0.05

- CTX-343 is a potent, peripherally restricted LPA1R antagonist with *in vitro* long receptor off rate, slow *in vivo* clearance and high oral bioavailability
- CTX-343 shows a dose-dependent LPA1R receptor occupancy at 3- and 24-hours after a single dose

### *In Vivo* Lung LPA1R Occupancy



# CTX-343 Inhibits LPA1-Induced Fibroblast Collagen Production



- CTX-343 inhibited LPA-induced COL1A1 in primary human lung fibroblasts with an IC<sub>50</sub> of 10.2 nM



## PIPE-307, an M1R Antagonist, for Depression



# PIPE-307: Two Shots on Goal for CNS

## DEPRESSION

**~280M**  
Patients Globally



Approved therapeutics suffer from major limitations

- Many patients fail to respond to available therapies
- Approved therapies have pronounced side effects

## RELAPSING-REMITTING MS

**~2M**  
Patients Globally



>20 FDA-approved DMTs that are only partially effective

- Approved therapies decrease annual relapse rate
- Do not directly remyelinate nerve fibers or reduce clinical disability

Completed 2 Phase 1 Healthy Volunteer trials with no dose-limiting AEs and desired target engagement

**2H 2024: J&J to initiate Phase 2 in depression**

**November 2023: Initiated Phase 2 VISTA trial in RRMS**

**PIPE-307 is a selective agent with an MoA that is clinically validated in two key CNS indications of high unmet need**

# Partnering Agreement with J&J for PIPE-307 – \$1B+ Potential Payments

- Leverages Contineum's expertise in precision neuroregeneration
- Contineum is leading Phase 2 development in RRMS, for which a study (VISTA) was initiated in late 2023
- J&J has the right, in its sole discretion, to further develop or elect not to develop PIPE-307 for RRMS
- J&J plans to initiate Phase 2 trial in depression in 2H 2024

**Johnson & Johnson**  
Innovative Medicine

Global development and license agreement for PIPE-307 in all indications



\$50M upfront, \$25M equity investment, milestones >\$1B, and tiered royalties (low-double digit to high-teens)



Contineum has opt-in right to fund-part Phase 3 development costs in return for an increase in royalty rates




J&J commitment to precision neuroscience



# Clinical Validation For Depression

## Scopolamine vs Placebo: Antidepressant Proof-of-concept<sup>1</sup>





\*MADRS – Montgomery-Asberg Depression Rating Scale <sup>1</sup>Furey and Drevets, Arch Gen Psych 2006

# PIPE-307 Shown to Enhance mEPSCs *Ex Vivo* In the Prefrontal Cortex

## STUDY DESIGN

- Mice were given a single dose of either PIPE-307 (30mg/kg) or vehicle
- 24h later brains *ex vivo* slice electrophysiology recordings were conducted from pyramidal neurons in layer V


## PIPE-307 Enhances Synaptic Transmission



PIPE-307 enhances spontaneous mEPSC frequency suggesting **presynaptic** involvement enhances **postsynaptic** mEPSC amplitude

# PIPE-307 Demonstrated Decreased Immobility Time in Mouse Forced Swim Test (Acute and Repeat Dosing Paradigms)


## Acute Dosing Paradigm



\*\*\*\*p<0.0001 versus vehicle

Consistent with the literature, scopolamine decreases immobility time - this effect is mimicked by the selective M1R antagonist PIPE-307

## Repeat Dosing Paradigm



\*\*\*\*p<0.0001 versus vehicle


Repeat dosing, once daily for 7 days, resulted in similar responses for both the 3 mg/kg and 30 mg/kg dosing groups



## PIPE-307, an M1R Antagonist, for RRMS

# Clinical Validation For Remyelination


Phase 2 clemastine ReBUILD RRMS trial



- Statistically significant improvement in VEP latency in both crossover and delayed treatment cohorts
- Key validation for the potential for remyelination with PIPE-307


# M1R Mechanistic Rationale And Preclinical Validation

## Blocking M1R Promotes Remyelination




## PIPE-307 Promotes Remyelination In Preclinical EAE Model

### Restored VEP-Latency



\*\*p<0.01, \*\*\*p<0.005 vs Vehicle treated

### Increased Myelination



\*\*\*p<0.001, \*\*\*\*p<0.0001, vs Vehicle treated



# PIPE-307: Phase 1 Healthy Volunteer Trials Support Both Indications

## Phase 1 SAD/MAD Trial Results

### Tolerability

- Well-tolerated across all dose cohorts
- No dose-limiting AEs or toxicity observed

### Pharmacokinetics

- Linear and dose-proportional PK (c/w preclinical studies)

### Exploratory


- Cognition: psychomotor, attention, learning, executive function
- No significant PK or dose-related effects on cognitive function

## Phase 1 PET Trial Results

- Established brain receptor uptake and PK relationship at pharmacologically active doses for CNS indications
- Plasma PK at target receptor occupancy well-tolerated

## PHASE 1 PET

Receptor occupancy (RO) vs plasma concentration



# VISTA: Phase 2 Randomized, Double-Blind Placebo-Controlled Trial in RRMS

## Key Eligibility Criteria

- 18-50y patient with RRMS
- Diagnosis of MS < 10 y
- EDSS: 0-6.0
- Stable DMT therapy



**6m dose-ranging**  
Daily oral dosing  
**1:1:1 Randomization**  
n=168

Placebo (n=56)

PIPE-307 Dose A (n=56)

PIPE-307 Dose B (n=56)

## Primary Objectives

Safety and tolerability

Low contrast letter acuity

## Key Secondary Objectives

Symbol digit modalities test

Timed 25-foot walk test

9-hole peg test

MRI (MTR and DTI)

Neurofilament light chain

## Illustrative 2.5% Sloan Low Contrast Letter Acuity



- Captures disability outside EDSS
- Correlates with OCT, MRI, VEP, QoL
- Considered one of the most sensitive tests to detect a treatment effect



## Key Clinical Milestones

# Catalyst-Rich 24 Months: Completed & Anticipated Clinical Milestones & Inflection Points

	2024	2025
<b>PIPE-791</b>	<ul style="list-style-type: none"> <li>Received Phase 1 Healthy Volunteers Clinical Data ✓</li> <li>File CTA with MHRA to Commence Phase 1b PET Study</li> <li>Receive Phase 1b PET Study Healthy Volunteer Clinical Data</li> </ul>	<ul style="list-style-type: none"> <li>Receive Phase 1b Brain &amp; Lung PET Study Clinical Data</li> <li>Complete Chronic tox &amp; IND to support Ph2 PoC trials</li> <li>Initiate Phase 2 IPF PoC Study</li> <li>Initiate Phase 2 Progressive MS PoC Study</li> </ul>
<b>CTX-343</b>	<ul style="list-style-type: none"> <li>Selected Development Candidate for Peripherally-Restricted LPA1R Antagonist ✓</li> </ul>	<ul style="list-style-type: none"> <li>File IND for Peripherally-Restricted LPA1R Antagonist</li> <li>Receive Phase 1 Healthy Volunteers Clinical Data</li> </ul>
<b>PIPE-307</b>	<ul style="list-style-type: none"> <li>Initiated Phase 2 RRMS PoC Study ✓</li> <li>Initiate Phase 2 Depression PoC Study*</li> </ul>	<ul style="list-style-type: none"> <li>Complete enrollment in Phase 2 RRMS PoC Study</li> </ul>

\*Phase 2 J&J depression study clinical data timing not disclosed at this time